FDA orders new vision loss warning for GLP-1s

The FDA is requiring safety labeling changes for GLP-1 receptor agonists over a potential increased risk of a rare eye condition that can cause vision loss. The agency is requiring drugs including Eli Lilly’s Mounjaro and Zepbound and Novo Nordisk’s Ozempic and Wegovy to add information about non-arteritic anterior ischemic optic neuropathy, or NAION, to […] The post FDA orders new vision loss warning for GLP-1s appeared first on Becker's Hospital Review | Healthcare News & Analys...